FBLG · FibroBiologics, Inc.
$1.76
-0.19 (-9.74%)
At close · Sep 3
Going-concern doubt
— flagged Jul 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the condensed consolidated financial statements. While management has implemented plans to obtain additional funding, these plans are not sufficient to alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Jul 31, 2026
Market Cap
$12.98M
Shares
6.66M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$18.65M
-67.1%
FY2025
Diluted EPS
-$8.40
-23.5%
FY2025
Operating Cash Flow
-$16.39M
-37.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| $8.2M | $7.41M | $4.5M | $2.37M | $1.15M | |
| $8.53M | $9.24M | $9.23M | $6.52M | $3.32M | |
| $16.73M | $16.65M | $13.74M | $8.89M | $4.47M | |
| -$16.73M | -$16.65M | -$13.74M | -$8.89M | -$4.47M | |
| — | $200K | — | $147K | $654K | |
| $133K | $247K | $251K | — | — | |
| -$1.41M | -$2M | $2.58M | -$213K | — | |
| $0 | $0 | $0 | $0 | $0 | |
| -$18.14M | -$18.65M | -$11.16M | -$16.49M | -$5.12M | |
| -$13.22M | — | -$11.16M | -$19.06M | -$5.12M | |
| USD/shares | -$5.27 | -$8.40 | -$6.80 | -$13.60 | -$3.60 |
| USD/shares | -$5.27 | -$8.40 | -$6.80 | -$13.60 | -$3.60 |
| shares | — | 2.23M | 1.64M | 1.41M | 1.41M |
| shares | — | 2.23M | 1.64M | 1.41M | 1.41M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Coverage backlog: 35 eligible filings and 0 covenant artifacts have no current-version terminal extraction result. This includes untouched sources and sources on the retry ladder.
No terminal debt extraction result is available yet; this is not evidence that the company has no debt.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.28×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.86×
Peer medians compare against the 207 similar-size Biotechnology companies (of 515 listed).
Key facts
CIK
1958777
CUSIP
31573L204
13F (30d)
15 filings
15 filers
Visit website
Investor relations